BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 2010;8:109. [PMID: 21047421 DOI: 10.1186/1479-5876-8-109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Y, Jia Y, Qi S, Wu C, Wu J, Zhang R, Li J, Guo Z. Comparison of Postoperative Prognosis Among HBV-Related, HCV-Related, and non-HBV non-HCV Hepatocellular Carcinomas: A Systematic Review and Meta-analysis. Hepat Mon 2022;22. [DOI: 10.5812/hepatmon-121820] [Reference Citation Analysis]
2 Otoguro T, Tanaka T, Kasai H, Kobayashi N, Yamashita A, Fukuhara T, Ryo A, Fukai M, Taketomi A, Matsuura Y, Moriishi K. Establishment of a Cell Culture Model Permissive for Infection by Hepatitis B and C Viruses. Hepatol Commun 2021;5:634-49. [PMID: 33860122 DOI: 10.1002/hep4.1653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hsiao YW, Chiu LT, Chen CH, Shih WL, Lu TP. Tumor-Infiltrating Leukocyte Composition and Prognostic Power in Hepatitis B- and Hepatitis C-Related Hepatocellular Carcinomas. Genes (Basel) 2019;10:E630. [PMID: 31434354 DOI: 10.3390/genes10080630] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
4 Li H, Li JR, Huang MH, Chen JH, Lv XQ, Zou LL, Tan JL, Dong B, Peng ZG, Jiang JD. Bicyclol Attenuates Liver Inflammation Induced by Infection of Hepatitis C Virus via Repressing ROS-Mediated Activation of MAPK/NF-κB Signaling Pathway. Front Pharmacol 2018;9:1438. [PMID: 30618739 DOI: 10.3389/fphar.2018.01438] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
5 Gladkovskaya O, Gun'ko YK, O'Connor GM, Gogvadze V, Rochev Y. In one harness: the interplay of cellular responses and subsequent cell fate after quantum dot uptake. Nanomedicine (Lond) 2016;11:2603-15. [PMID: 27618947 DOI: 10.2217/nnm-2016-0068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Tsai WT, Lo YC, Wu MS, Li CY, Kuo YP, Lai YH, Tsai Y, Chen KC, Chuang TH, Yao CH, Lee JC, Hsu LC, Hsu JT, Yu GY. Mycotoxin Patulin Suppresses Innate Immune Responses by Mitochondrial Dysfunction and p62/Sequestosome-1-dependent Mitophagy. J Biol Chem 2016;291:19299-311. [PMID: 27458013 DOI: 10.1074/jbc.M115.686683] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
7 Peng Q, Lao X, Chen Z, Lai H, Deng Y, Wang J, Mo C, Sui J, Wu J, Zhai L. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One. 2013;8:e82773. [PMID: 24376578 DOI: 10.1371/journal.pone.0082773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
8 Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5(10): 528-540 [PMID: 24179612 DOI: 10.4254/wjh.v5.i10.528] [Cited by in Crossref: 136] [Cited by in F6Publishing: 133] [Article Influence: 15.1] [Reference Citation Analysis]
9 Othman MS, Aref AM, Mohamed AA, Ibrahim WA. Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients. ISRN Hepatol 2013;2013:412317. [PMID: 27335826 DOI: 10.1155/2013/412317] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
10 Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, Di Stasio M, Paolisso G, Castello G, Colonna G. Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One. 2012;7:e39486. [PMID: 22745767 DOI: 10.1371/journal.pone.0039486] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359-366. [PMID: 22334456 DOI: 10.1634/theoncologist.2011-0313] [Cited by in Crossref: 105] [Cited by in F6Publishing: 116] [Article Influence: 10.5] [Reference Citation Analysis]
12 Choi J. Oxidative stress, endogenous antioxidants, alcohol, and hepatitis C: pathogenic interactions and therapeutic considerations. Free Radic Biol Med. 2012;52:1135-1150. [PMID: 22306508 DOI: 10.1016/j.freeradbiomed.2012.01.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
13 Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108. [PMID: 21933440 DOI: 10.1186/1477-7819-9-108] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
14 Hevezi PA, Tom E, Wilson K, Lambert P, Gutierrez-Reyes G, Kershenobich D, Zlotnik A. Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus. Autoimmunity 2011;44:532-42. [PMID: 21864061 DOI: 10.3109/08916934.2011.592881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 De Flora S, Bonanni P. The prevention of infection-associated cancers. Carcinogenesis. 2011;32:787-795. [PMID: 21436188 DOI: 10.1093/carcin/bgr054] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]